After the New York Mets acquired reliever Tyler Clippard yesterday from the Oakland Athletics, the team felt they have upgraded their bullpen to help them push for a playoff spot.
Well, their bullpen took a hit on Tuesday afternoon, as Major League Baseball announced that right-hander Jenrry Mejia has been suspended 162 games for his second performance enhancing drug (PED) violation.
#Mets’ Mejia gets 162-game ban for second PED violation.
— Ken Rosenthal (@Ken_Rosenthal) July 28, 2015
The 25-year old was previously suspended for 80 games without pay earlier in the season after he tested positive for Stanozolol, a performance-enhancing substance. According to Joel Sherman of the NY Post, Mejia tested positive again for Stanozolol and Boldenone, forcing Major League Baseball to suspend the reliever for a second time.
For the Mets, this is a huge blow. Although he only has appeared in seven games this season due to the suspension and an injury that forced him on the disabled list, the club was relying on Mejia to help them down the stretch, especially after his 2014 season in which he saved 28 games for the club. As he was already ruled ineligible to participate in the postseason due to the first suspension, the team knew he would only be able to impact them during the regular season.
Moving forward, it will be interesting to see how the Mets handle this situation. It was reported that the club was furious with his first failed drug test, and with this suspension, it could mark the end of his time with the organization. Mejia is arbitration eligible after the season.
Shortly after the announcement, the Mets organization released a statement regarding the issue:
“We were extremely disappointed when informed of Jenrry’s second suspension for violating MLB’s Joint Drug Prevention Program. We fully support MLB’s policy toward eliminating performance enhancing substances from the sport.”